

K. G. Ramawat (Ed.)

Herbal Drugs: Ethnomedicine to Modern Medicine



Springer

Herbal Drugs: Ethnomedicine to Modern Medicine

K.G. Ramawat (Ed.)

Herbal Drugs: Ethnomedicine to Modern Medicine

 Springer

Editor

Prof. Dr. K.G. Ramawat
M.L. Sukhadia University
Botany Dept.
Udaipur-313002
India

ISBN: 978-3-540-79115-7

e-ISBN: 978-3-540-79116-4

Library of Congress Control Number: 2008935113

© Springer-Verlag Berlin Heidelberg 2009

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Cover design: WMXDesign GmbH, Heidelberg

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com

About the editor

Professor K.G. Ramawat (born in 1952) received his M.Sc. (1974) and Ph.D. (1978, Plant Biotechnology) from the University of Jodhpur, Jodhpur, India and became a faculty member in January of 1979. He joined M.L. Sukhadia University as an Associate Professor in 1991 and became a Professor in 2001. He served as Head of the Department of Botany (2001–2004), was in charge of the Department of Biotechnology (2003–2004), was a member of the task force on medicinal and aromatic plants at the Department of Biotechnology (Government of India, New Delhi; 2002–2005), and was a coordinator of the UGC-DRS and DST-FIST programs (2002–2007). He did his postdoctoral study at the University of Tours, France (1983–85) and subsequently worked as visiting professor at the University of Tours (1991) and University of Bordeaux 2, France (1995, 1999, 2003, 2006). He visited Poland under the auspices of an INSA-PAN academic exchange program (2005). He has published more than 100 research papers and review articles in reputed journals and books. He has edited two books on the biotechnology of secondary metabolites and of medicinal plants (Scientific Publishers, Enfield, USA and Springer verlag, Heidelberg, Germany). Professor Ramawat has completed several major research projects from UGC, CSIR, ICAR, DBT, and DST, and has supervised the doctoral theses of 16 students. He has been a member of the Plant Tissue Culture Association of India since 1991.

Preface

Considerable progress has been made in our healthcare system, in particular with respect to sensitive diagnostic tools, reagents and very effective and precise drugs. On the other hand, high-throughput screening technology can screen vast numbers of compounds against an array of targets in a very short time, and leads thus obtained can be further explored. In developing countries, the exploding population exerts pressure not only on natural resources but also on the human population itself, whose members strive to become successful and advance in society. This leads to increased blood pressure, anxiety, obesity-associated lipid disorders, cardiovascular diseases and diabetes. Most of these diseases result in disturbed family life, including sexual behaviour.

Despite technological developments, herbal drugs still occupy a preferential place in a majority of the population in the Third World and terminal patients in the West. Herbal drugs, in addition to being cost effective and easily accessible, have been used since time immemorial and have passed the test of time without having any side effects. The multitarget effects of herbs (holistic approaches) are the fundamental basis of their utilization. This approach is already used in traditional systems of medicine like Ayurveda, which has become more popular in the West in recent years. However, the integration of modern science with traditional uses of herbal drugs is of the utmost importance if ones wishes to use ancient knowledge for the betterment of humanity. This book will try to bridge this gap and will be a valuable source for herbalists, traditional and modern medical practitioners, and researchers in botany, ethnobotany, pharmacy, phytochemistry and agriculture. Contributions on herbs used for beneficial effects on memory, sexual behaviour, neurodegeneration, erectile dysfunction, inflammation, cardiovascular diseases, cancer prevention, stroke and central nervous system disorders will provide vital information to readers.

Finally, I would like to acknowledge my contributors, who have gone to great lengths to ensure the high scientific quality of the book. I would also like to thank my colleagues at Springer.

July 2008

K.G. Ramawat

Contents

1	Medicinal Plants: A Renewable Resource for Novel Leads and Drugs	1
	<i>R. Verpoorte</i>	
1.1	Introduction	2
1.2	Conclusion	4
	References	5
2	The Chemical Diversity of Bioactive Molecules and Therapeutic Potential of Medicinal Plants	7
	<i>K.G. Ramawat, S. Dass and Meeta Mathur</i>	
2.1	Introduction	7
2.2	Traditional Use of Medicinal Plants	8
2.3	Ancient Systems of Medicine	9
2.3.1	Traditional Indian Medicine	9
2.3.2	Traditional Chinese Medicine	10
2.3.3	Traditional Egyptian Medicine	11
2.3.4	Traditional Arabic Medicine	11
2.3.5	African, European and Other Traditional Systems of Medicine	11
2.4	Exploration of Medicinal Plants	12
2.5	Approaches to Drug Discovery	13
2.6	Bioactive Molecules of Medicinal Plants	15
2.6.1	Alkaloids	16
2.6.2	Phenolics	21
2.6.3	Terpenes	24
2.7	Conclusion	29
	References	30

3	Indigenous People and Forests: Perspectives of an Ethnobotanical Study from Rajasthan (India)	33
	<i>S.S. Katewa</i>	
3.1	Introduction	33
3.2	Study Site and People	35
3.3	Observations	35
	3.3.1 Healthcare	35
3.4	Wild Food Plants	53
3.5	Conclusions	54
	References	55
4	Ginseng and Male Sexual Behavior	57
	<i>Laura L. Murphy and James S. Ferraro</i>	
4.1	Introduction to Ginseng	58
4.2	Physiology of an Erection	58
4.3	Ginseng and Copulatory Behavior – Animal Studies	60
4.4	Ginseng and Erectile Function	61
4.5	Nitric Oxide	62
4.6	Central Nervous System Actions of Ginseng	63
4.7	Conclusions	64
	References	64
5	Herbal Treatments for Erectile Dysfunction	67
	<i>Jyoti Shah</i>	
5.1	Introduction	67
5.2	Herbal Treatments for ED	68
	5.2.1 <i>Cola acuminata</i>	69
	5.2.2 <i>Damiana</i>	69
	5.2.3 <i>DHEA</i>	70
	5.2.4 <i>Fo-Ti</i>	70
	5.2.5 <i>Gamma-Butyrolactone (GBL)</i>	70
	5.2.6 <i>Ginkgo biloba</i>	70
	5.2.7 <i>Ginseng</i>	71
	5.2.8 <i>Horny Goat Weed</i>	72
	5.2.9 <i>L-Arginine</i>	73
	5.2.10 <i>Maca</i>	74
	5.2.11 <i>Muira Puama</i>	75
	5.2.12 <i>Propionyl-L-Carnitine</i>	75
	5.2.13 <i>Reishi</i>	76
	5.2.14 <i>Tongkat Ali</i>	76
	5.2.15 <i>Tribulus</i>	77
	5.2.16 <i>Yohimbine</i>	77
	References	79

6	<i>Harpagophytum procumbens</i> – Traditional Anti-inflammatory Herbal Drug with Broad Therapeutic Potential	81
	<i>G.P. McGregor</i>	
6.1	Introduction	82
6.2	The Status and Use of Hp-Containing Products	84
6.3	Chemical Constituents of Hp Extracts	84
6.4	Pharmacological Properties	85
6.4.1	In Vivo Anti-Inflammatory Effects of Hp Extracts and Harpagoside	86
6.4.2	In Vivo Analgesic Effects of Hp Extracts and Harpagoside	87
6.4.3	Effects of Hp Extracts and Harpagoside on Pro-Inflammatory Molecular Targets – Eicosanoids, Cytokines, Second-Messenger Pathways and Effector Molecules	87
6.4.4	Possible Mode of Action of Hp	90
6.5	Secondary Pharmacology of Hp	91
6.6	Clinical Studies of Hp	92
6.7	Toxicological Considerations	93
6.8	Concluding Remarks and Outlook	93
	References	94
7	The Role of Curcumin in Modern Medicine	97
	<i>Gautam Sethi, Bokyung Sung and Bharat B. Aggarwal</i>	
7.1	Introduction	97
7.2	Isolation and Chemical Properties of Curcumin	98
7.3	Antioxidant Properties of Curcumin	98
7.4	Molecular Targets of Curcumin	99
7.4.1	Cytokines and Growth Factors	101
7.4.2	Receptors	101
7.4.3	Transcription Factors	102
7.4.4	Proinflammatory Enzymes	102
7.4.5	Protein Kinases	103
7.4.6	Cell Cycle	103
7.4.7	Adhesion Molecules	103
7.4.8	Antiapoptotic Proteins	104
7.4.9	Multidrug Resistance	104
7.5	Disease Targets of Curcumin	104
7.5.1	Anticancer Effects	104
7.5.2	Skin Diseases	107
7.5.3	Diabetes	107
7.5.4	Rheumatoid Arthritis	107
7.5.5	Multiple Sclerosis	108
7.5.6	Alzheimer's Disease	109
7.5.7	Inflammatory Bowel Disease	109

7.5.8	Cystic Fibrosis	109
7.5.9	Others	109
7.6	Structure Activity Relationship of Curcumin	110
7.7	Conclusions	110
	References	111
8	Proprietary Herbal Medicines in Circulatory Disorders: Hawthorn, Ginkgo, Padma 28	115
	<i>Jörg Melzer and Reinhard Saller</i>	
8.1	Introduction	115
8.2	Hawthorn	116
8.2.1	Plant	116
8.2.2	Tradition	117
8.2.3	Chemistry and Pharmacology	117
8.2.4	Clinical Evidence	119
8.2.5	Hawthorn Leaves and Flowers in CHF	119
8.2.6	Hawthorn Berries in CHF	122
8.2.7	Safety	123
8.2.8	Summary	123
8.3	Padma 28	124
8.3.1	Plants	124
8.3.2	Tradition	124
8.3.3	Chemistry and Pharmacology	126
8.3.4	Clinical Evidence	127
8.3.5	Summary	128
8.4	Ginkgo	129
8.4.1	Plant	129
8.4.2	Tradition	129
8.4.3	Chemistry and Pharmacology	130
	References	132
9	The Effects of the Green Tea Polyphenol Epigallocatechin Gallate on the Central Nervous, Endocrine, and Innate Immune Systems . . .	137
	<i>Lisa A. Beltz</i>	
9.1	Introduction	137
9.2	The Effects of EGCG on the Central Nervous System	138
9.2.1	Alzheimer's Disease	139
9.2.2	Parkinson's Disease	140
9.2.3	Huntington's Disease	141
9.2.4	Amyotrophic Lateral Sclerosis (ALS)	142
9.2.5	Ischemic Conditions/Stroke	142
9.2.6	Multiple Sclerosis	143
9.2.7	Anxiety	143
9.2.8	Memory	144
9.2.9	HIV-Associated Dementia (HAD)	144

9.2.10	Neuronal Activity	144
9.2.11	Neurotransmitters and Their Receptors	145
9.3	The Effects of EGCG on the Endocrine System (Table 9.2)	146
9.3.1	Production of Hormones and Consequent Events	146
9.3.2	Diseases Involving Insulin Alterations	147
9.4	Effects of EGCG on Aspects of the Innate Immune System	148
9.4.1	Cytokine Production	148
9.4.2	The Role of Reactive Oxygen Species	149
9.4.3	The Role of Reactive Nitrogen Species	150
9.5	Conclusions	150
	References	151
10	Natural Products in Cancer Chemoprevention and Chemotherapy	153
	<i>K.G. Ramawat and Shaily Goyal</i>	
10.1	Introduction	153
10.2	Cancer Chemoprevention	155
10.3	Anticancer Drugs from Microorganisms	158
10.4	Anticancer Drugs from Plants	159
10.4.1	Podophyllotoxins	159
10.4.2	Vinblastine	161
10.4.3	Taxol	161
10.4.4	Camptothecin	163
10.4.5	Others	163
10.5	Mechanism of Action	164
10.6	Herb-Drug Interactions	167
10.7	Conclusions	168
	References	168
11	Artemisinin: A Versatile Weapon from Traditional Chinese Medicine	173
	<i>Thomas Efferth</i>	
11.1	Introduction	174
11.2	Use of Artemisinin in Traditional Chinese Medicine	174
11.3	Mode of Action of Artemisinin	175
11.4	Activity Against Malaria	177
11.5	Activity Against Cancer	179
11.6	Activity Against Schistosomiasis	181
11.7	Activity Against Viral Infections	182
11.7.1	Human Cytomegalovirus	182
11.7.2	Human Hepatitis B Virus (HBV)	184
11.7.3	Human Hepatitis C Virus (HCV)	185
11.7.4	Bovine Viral Diarrhea Virus (BVDV)	186
11.7.5	Other Viruses	186
11.8	Side Effects of Artemisinin	187
11.9	Conclusion and Perspectives	188
	References	189

12	Anticancer and Immunomodulatory Properties of <i>Tinospora</i>	195
	<i>Anil Mittal and Rana P. Singh</i>	
12.1	Introduction	196
12.2	Effect of <i>Tinospora</i> on Carcinogen/Drug Metabolism and Antioxidant Systems	198
12.3	Anticancer Activity of <i>Tinospora</i>	198
12.4	<i>Tinospora</i> Inhibits Tumor Angiogenesis	199
12.5	<i>Tinospora</i> Inhibits Cancer Metastasis	199
12.6	Radioprotective Potential of <i>Tinospora</i>	200
12.7	<i>Tinospora</i> Activates Tumor-Associated Macrophages of Dalton's Lymphoma	200
12.8	Immunostimulating Properties of <i>Tinospora</i>	201
12.9	Mechanism of Macrophage Activation by (1 → 4) α-D Glucan from <i>Tinospora</i>	201
12.10	G1-4A, an Immunomodulatory Polysaccharide from <i>Tinospora</i>	202
12.11	Hepatoprotective Properties of <i>Tinospora</i>	203
12.12	Summary	203
	References	204
13	Safety and Efficacy of Phytomedicines in Cancer	
	Prevention and Treatment	207
	<i>Giuseppina Benoni and Laura Cuzzolin</i>	
13.1	Introduction	207
13.1.1	Reasons for Using Phytomedicines in Cancer Treatment and Prevention	208
13.2	Methods	209
13.3	Epidemiological data	209
13.4	Herbs Commonly Used in Cancer Treatment and Prevention	210
13.5	Herbs for Treating the Side Effects of Chemotherapy and Radiation	212
13.6	Safety Data of Herbal Compounds in Cancer Patients	214
13.7	Conclusions	217
	References	218
14	Novel Leads from Herbal Drugs for Neurodegenerative Diseases	221
	<i>Maheep Bhatnagar</i>	
14.1	Introduction	221
14.2	Ayurveda, Herbal Drugs, and the Central Nervous System	222
14.3	Neurodegenerative Diseases:	224
14.4	Medicinal Plants, Neurodegenerative Diseases, and Therapeutics:	226
14.5	Plants Native to India	229
14.5.1	<i>Acorus calamus</i>	229
14.5.2	<i>Asparagus racemosus</i>	229
14.5.3	<i>Bacopa monnieri</i>	229
14.5.4	<i>Celastrus peniculatus</i>	230

14.5.5	Centella asiatica	230
14.5.6	Convolvulus pleuricaulis	230
14.5.7	Crocus sativus	231
14.5.8	Curculigo orchioides	231
14.5.9	Curcuma longa	231
14.5.10	Cyprus rotundus	232
14.5.11	Ficus religiosa	232
14.5.12	Ginkgo biloba	232
14.5.13	Mucuna pruriens	233
14.5.14	Nardostachys jatamanasi	233
14.5.15	Plumbago zeylanica	233
14.5.16	Semecarpus anacardium	234
14.5.17	Swertia chirayita	234
14.5.18	Withania somnifera	234
14.6	Plants not Native to India	235
14.6.1	Galanthus wornorii	235
14.6.2	Huperzine serrata	235
14.6.3	Lavandula stoechas	235
14.7	Conclusion	236
	References	236
15	Traditional Medicine for Memory Enhancement	239
	<i>Melanie-Jayne R. Howes and Peter J. Houghton</i>	
15.1	Introduction	240
15.1.1	Cognitive Disorders	240
15.1.2	Alzheimer's Disease	241
15.1.3	Cholinergic Function	241
15.1.4	Symptoms Related to Memory Disorders in Traditional Practices of Medicine	242
15.2	Activities Relevant to the Treatment of Cognitive Disorders	243
15.2.1	Precursors of Acetylcholine	243
15.2.2	Muscarinic Receptor Stimulation	243
15.2.3	Nicotinic Receptor Stimulation/Nicotinic Agonists	244
15.2.4	Cholinesterase Inhibitors	245
15.2.5	Anti-Inflammatory Activity	245
15.2.6	Antioxidant Activity	246
15.2.7	Estrogenic Activity	247
15.2.8	NMDA Antagonists	249
15.3	Plants as a Source of Useful Therapeutic Agents in Cognitive Diseases	249
15.4	Plants Used in Traditional Ayurvedic Medicine	250
15.4.1	<i>Areca catechu</i> L.	250
15.4.2	<i>Bacopa monniera</i> Wettst.	251
15.4.3	<i>Centella asiatica</i> (L.) Urb.	252

15.4.4	<i>Celastrus paniculatus</i> Willd.	253
15.4.5	<i>Clitoria ternatea</i> L.	254
15.4.6	<i>Curcuma longa</i> L.	255
15.4.7	<i>Withania somnifera</i> (L.) Dunal	256
15.5	Plants Used in Traditional Chinese Medicine (TCM)	259
15.5.1	<i>Evodia rutaecarpa</i> (Juss.) Benth.	259
15.5.2	<i>Ginkgo biloba</i> L.	260
15.5.3	<i>Huperzia serrata</i> (Thunb.) Trevis	263
15.5.4	<i>Magnolia officinalis</i> Rehder & E.H.Wilson	265
15.5.5	<i>Polygala tenuifolia</i> Willd.	266
15.5.6	<i>Salvia miltiorrhiza</i> Bunge	268
15.6	Plants Used in Traditional European Medicine	271
15.6.1	<i>Galanthus</i> and <i>Narcissus</i> Species	271
15.6.2	<i>Melissa officinalis</i> L.	272
15.6.3	<i>Salvia officinalis</i> L. and <i>S. lavandulifolia</i> Vahl	274
15.7	Plants Used in African and South American Traditional Medicine .	276
15.7.1	<i>Physostigma venenosum</i> Balf.	276
15.7.2	<i>Pilocarpus</i> Species	277
15.7.3	<i>Ptychopetalum olacoides</i> Benth.	278
15.8	Conclusions	279
	References	280
16	Neuroprotective Herbs for Stroke	293
	<i>Hocheol Kim</i>	
16.1	Introduction	294
16.2	Stroke Therapy in Traditional Medicine	295
16.3	Neuroprotective Herbs for Stroke	296
16.4	Single Herb Extracts and Their Active Compounds	300
16.4.1	<i>Panax ginseng</i>	300
16.4.2	<i>Salvia miltiorrhiza</i>	302
16.4.3	<i>Ginkgo biloba</i>	302
16.4.4	<i>Acanthopanax senticosus</i>	303
16.4.5	<i>Scutellaria baicalensis</i>	304
16.4.6	<i>Camellia sinensis</i> (Green tea)	304
16.4.7	<i>Pueraria thunbergiana</i> , <i>P. lobata</i>	304
16.4.8	<i>Cnidium officinale</i> , <i>Ligusticum chuanxiiong</i>	305
16.4.9	<i>Magnolia officinalis</i>	306
16.4.10	<i>Angelica gigas</i> , <i>A. sinensis</i>	306
16.4.11	<i>Rhodiola rosea</i>	307
16.4.12	<i>Paeonia suffruticosa</i> , <i>P. lactiflora</i>	307
16.4.13	<i>Bombycis Corpus</i>	307
16.4.14	<i>Corydalis yanhusuo</i>	308
16.4.15	<i>Acorus gramineus</i>	308
16.4.16	<i>Coptis japonica</i>	309
16.4.17	<i>Phellodendri cortex</i>	309

16.4.18	<i>Huperzia serrata</i>	309
16.4.19	<i>Menispermum dauricum</i>	310
16.4.20	<i>Gardenia jasminoides</i>	310
16.4.21	<i>Uncaria rhynchophylla</i>	310
16.4.22	<i>Schisandra chinensis</i>	311
16.4.23	<i>Carthamus tinctorius</i>	311
16.4.24	Other Herbs	311
16.5	Multiherb Extracts	312
16.5.1	<i>Huanglianjiedu</i> Decoction	312
16.5.2	<i>Buyanghuanwu</i> Decoction	313
16.5.3	Woohwangchungsim-won	313
16.5.4	Shengmaisai	314
16.5.5	<i>Qizhu</i> Decoction	314
16.6	Conclusion	314
	References	315
17	Biological Activity of Ginkgo	321
	<i>Ján Lehotský, Peter Kaplan, Martina Pavlikova, Peter Urban and Beata Saniova</i>	
17.1	Introduction	321
17.2	Pharmacokinetics	322
17.3	Treatment of Cerebral Ischemia	323
17.3.1	Antioxidant/Scavenger Action	323
17.3.2	Other Anti-Ischemic Effects	327
	References	330
18	Vitamin E Metabolic Modulation in Plants	333
	<i>Guo Juan, Gongshe Liu, Chen Shuangyan and Amina A. Aly</i>	
18.1	Introduction	334
18.2	Vitamin E History	336
18.3	Vitamin E Structure	336
18.4	Vitamin E Biosynthetic Pathway in Plants	337
18.5	Strategies for Vitamin E Metabolic Engineering in Plants	339
18.6	Isolation and Identification of Genes in the Vitamin E Biosynthetic Pathway	340
18.7	Engineering Plants to Improve Vitamin E Content	343
18.8	Engineered Plants to Modulate Vitamin E Composition	347
18.9	Conclusions and Perspectives	348
	References	349
19	Herbal Drugs of Abuse	353
	<i>Jochen Beyer, Olaf H. Drummer and H.C. Hans H. Maurer</i>	
19.1	Introduction	354
19.2	Historical Background of Herbal Drugs of Abuse	354
19.3	Classical Herbal Drugs of Abuse	356

19.3.1	Cannabis and Tetrahydrocannabinol	356
19.3.2	Coca and Cocaine	357
19.3.3	Poppies and Opiates	360
19.4	Current Herbal Drugs of Abuse	361
19.4.1	Nightshades	361
19.4.2	Ayahuasca	362
19.4.3	Morning Glory and Lysergic Acid Amide	362
19.4.4	Ephedra and Kath	363
19.4.5	Iboga	364
19.4.6	Nutmeg	364
19.4.7	<i>Salvia divinorum</i>	365
19.4.8	Kava	366
	References	367
20	Biological Activities of Kinetin	369
	<i>Kalina Duszka, Brian F.C. Clark, Frank Massino and Jan Barciszewski</i>	
20.1	Introduction	370
20.2	Kinetin Occurrence, Structure, and Chemical Properties	370
20.3	Synthesis and Modification of Kinetin	371
20.4	Biological Activities of Kinetin	372
20.4.1	Influence of Kinetin on Plants	372
20.4.2	Influence of Kinetin on Animals	374
20.5	Perspectives	378
	References	379
21	Safety Issues of Phytomedicines in Pregnancy and Paediatrics	381
	<i>Laura Cuzzolin and Giuseppina Benoni</i>	
21.1	Introduction	382
21.2	Methods	382
21.3	Herbal Products in Pregnancy	382
21.3.1	Epidemiological Data	383
21.3.2	Herbs Commonly Used during Pregnancy	384
21.3.3	Safety Data	385
21.4	Herbal Products in Paediatrics	388
21.4.1	Epidemiological Data	388
21.4.2	Herbs Commonly Used in Children	390
21.4.3	Safety Data	391
21.5	Conclusions	393
	References	394
	Index	397

List of Contributors

Bharat B. Aggarwal Cytokine Research Laboratory, Departments of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA, e-mail: aggarwal@mdanderson.org

Amina A. Aly Atomic Energy Authority, National Centre for Radiation Research and Technology, Natural Products Department, 110 Nile Street, Dokki, Cairo, Egypt, e-mail: liugs@ibcas.ac.cn

Jan Barciszewski Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland, e-mail: Jan.Barciszewski@ibch.poznan.pl

Lisa A. Beltz Department of Biology, University of Northern Iowa, Cedar Falls, IA 50614, USA, e-mail: lisa.beltz@uni.edu

Giuseppina Benoni Department of Medicine & Public Health, Section of Pharmacology, University of Verona, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 37134 Verona, Italy, e-mail: Giuseppina.benoni@univr.it

Jochen Beyer Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83 Kavanagh St, Southbank, Victoria 3006, Australia, e-mail: jochenb@vifm.org

Maheep Bhatnagar Animal Biotechnology and Neuroscience Laboratory, Department of Zoology, M.L. Sukhadia University, Udaipur-313001, India, e-mail: mhatnagar@yahoo.com, m.maheep@gmail.com

Brian F.C. Clark Department of Molecular and Structural Biology, Aarhus University, Gustav Wieds Vej 10C, 8000 Aarhus C, Denmark, e-mail: bffc@mb.au.dk

Laura Cuzzolin Department of Medicine & Public Health, Section of Pharmacology, University of Verona, Policlinico G.B., Rossi, Piazzale L.A. Scuro, 37134 Verona, Italy, e-mail: laura.cuzzolin@univr.it

S. Dass Laboratory of Biomolecular Technology, Department of Botany, M.L. Sukhadia University, Udaipur-313001, India

Olaf H. Drummer Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83 Kavanagh St, Southbank, Victoria 3006, Australia

Kalina Duszka Institute for Genomics and Bioinformatics, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria, e-mail: kalina.duszka@tugraz.at

Thomas Efferth German Cancer Research Center, Pharmaceutical Biology (C015), Im Neuenheimer Fedl 280, 69120 Heidelberg, Germany, e-mail: t.efferth@dkfz.de

James S. Ferraro Department of Physiology, Southern Illinois, University School of Medicine, Carbondale, IL 62901-6512, USA

Shaily Goyal Laboratory of Biomolecular Technology, Department of Botany, M.L. Sukhadia University, Udaipur-313001, India

Peter J. Houghton Department of Pharmacy, King's College London, Franklin-Wilkins Building, London, UK

Melanie-Jayne R. Howes Royal Botanic Gardens, Jodrell Laboratory, Kew, Richmond, TW9 3AB, Surrey, UK, e-mail: m.howes@kew.org

Guo Juan Key Laboratory of Photosynthesis and Environmental Molecular Physiology, Institute of Botany, Chinese Academy of Sciences, 20 Nanxincun, Xiangshan, Haidian District, 100093 Beijing, P.R. China

Peter Kaplan Comenius University, Jessenius Faculty of Medicine, Department of Medical Biochemistry, Malá Hora 4, 037 54 Martin, Slovak Republic

S.S. Katewa Laboratory of Ethnobotany and Agrostology, Department of Botany, University College of Science, M.L. Sukhadia University, Udaipur-313001, India, e-mail: sskatewa@yahoo.com

Hocheol Kim Department of Herbal Pharmacology, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Korea, e-mail: hckim@khu.ac.kr

Ján Lehotský Comenius University, Jessenius Faculty of Medicine, Department of Medical Biochemistry, Malá Hora 4, 037 54 Martin, Slovak Republic, e-mail: Lehotsky@jfmed.uniba.sk

Gongshe Liu Key Laboratory of Photosynthesis and Environmental Molecular Physiology, Institute of Botany, Chinese Academy of Sciences, 20 Nanxincun, Xiangshan, Haidian District, 100093 Beijing, P.R. China

Frank Massino Senetek PLC, 851 Latour Court, Suite A, Napa, CA 94588, USA, e-mail: FMSenetek@aol.com

Meeta Mathur Laboratory of Biomolecular Technology, Department of Botany, M.L. Sukhadia University, Udaipur-313001, India

H.C. Hans H. Maurer Department of Experimental and Clinical Toxicology, Saarland University, 66421 Homburg/Saar, Germany

G.P. McGregor Philipps-University of Marburg, Faculty of Medicine, Deutschhausstraße 2, 35037 Marburg, Germany, e-mail: mcgregor@staff.uni-marburg.de

Jörg Melzer Institute of Complementary Medicine, Department of Internal Medicine, University Hospital Zurich, Raemistr. 100, 8091 Zurich, Switzerland, e-mail: joerg.melzer@usz.ch

Anil Mittal Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

Laura L. Murphy Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL 62901–6512, USA, e-mail: lmurphy@siu.edu

Martina Pavlikova Comenius University, Jessenius Faculty of Medicine, Department of Medical Biochemistry, Malá Hora 4, 037 54 Martin, Slovak Republic

K.G. Ramawat Laboratory of Biomolecular Technology, Department of Botany, M.L. Sukhadia University, Udaipur-313001, India, e-mail: kg_ramawat@yahoo.com

Reinhard Saller Institute of Complementary Medicine, Department of Internal Medicine, University Hospital Zurich, Raemistr. 100, 8091 Zurich, Switzerland

Beata Saniova Clinic of Anesthesiology and Intensive Medicine, Kollarova 2, SK-03601 Martin, Slovak Republic

Gautam Sethi Cytokine Research Laboratory, Departments of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

Jyoti Shah Department of Urology, St. George's Hospital, Blackshaw Road, London SW17 0QT, UK, e-mail: jyoti.shah@imperial.ac.uk

Chen Shuangyan Key Laboratory of Photosynthesis and Environmental Molecular Physiology, Institute of Botany, Chinese Academy of Sciences, 20 Nanxincun, Xiangshan, Haidian District, 100093 Beijing, P.R. China

Rana P. Singh Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India, e-mail: rana_singh@mail.jnu.ac.in

Bokyung Sung Cytokine Research Laboratory, Departments of Experimental Therapeutics, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

Peter Urban Comenius University, Jessenius Faculty of Medicine, Department of Medical Biochemistry, Malá Hora 4, 037 54 Martin, Slovak Republic

R. Verpoorte Department of Pharmacognosy, Section Metabolomics, Institute of Biology Leiden, PO Box 9502, 2300RA Leiden, The Netherlands, e-mail: VERPOORT@LACDR.LeidenUniv.NL

Chapter 1

Medicinal Plants: A Renewable Resource for Novel Leads and Drugs

R. Verpoorte

Abstract Present-day drug development is strongly focused on finding active compounds on well-defined targets using high throughput screening approaches. Unfortunately it seems that this approach is becoming less and less successful, as in most cases already good compounds are on the market, and the rapidly rising costs of drug development will make it increasingly difficult to make an economically competitive novel drug for any major disease. In other words, the reductionist approach presently used is becoming less successful. The time has come to rethink drug development. Many Western medicines are based on traditional knowledge from Europe and the Mediterranean region. This is why interest is rapidly increasing in Indian and Chinese medicine, both of which represent a very long tradition of apparently safe use. However, these healthcare systems are different from Western medicine, so novel methods are required to verify the efficacy and safety of the therapies. As it often concerns personalized medication with complex mixtures, a reductionist approach of screening for a single active compound on a known target will in many cases not be successful, as more than one target may be involved; in addition, and complicating the situation even more, synergism and prodrugs may be involved. Systems biology as a novel holistic way of dealing with biological problems seems here an interesting option. Systems biology means proceeding without a hypothesis, just observing, measuring as many parameters as possible in a biological system and afterwards using chemometrics to reveal any meaning in the data. This approach has already proven successful in studying medicinal plants and, in combination with the classical natural-product-based drug lead finding, is expected to be a major issue in the coming years. As present-day patent laws require innovative and unexpected findings, the development of old knowledge does not fit this requirement. Therefore, to support the development of evidence-based traditional medicines, it would be of great interest if some sort of protection could be obtained for companies developing such medicines so that they could earn back their huge R&D investments.

R. Verpoorte (✉)

Department of Pharmacognosy, Section Metabolomics, Institute of Biology Leiden, PO Box 9502, 2300RA Leiden, The Netherlands
e-mail: VERPOORT@LACDR.LeidenUniv.NL

Keywords Herbal medicines · Traditional medicine · Systems biology

1.1 Introduction

Since ancient times humans have explored their environment for plants that could be used to cover all their basic needs: food, shelter, fuel and health. This has resulted in the use of a large number of plants; in particular, food plants' extensive breeding has resulted in high-yield crops. In the case of medicinal plants, such breeding has largely not yet taken place as nature could provide a sufficient supply. The number of medicinal plants has been estimated to be on the order of 40,000 to 70,000 [1], which means that almost 25% of all plant species have some sort of medicinal use somewhere in the world. This heritage from our ancestors has continued to develop in Western medicine and has resulted in the isolation and production of pure active compounds (e.g. morphine, atropine and digoxin) and later in the development of novel synthetic compounds based on this knowledge (e.g. local anaesthetics based on cocaine, analgesics based on morphine). Some of these synthetics based on natural products have been very successful, e.g. acetylsalicylate, which development was based on the use of *Salix* bark as analgesic. In other cases the result has not been so successful, e.g. the acetyl derivative of morphine (heroin). This illustrates that many medicines in the West have originated in phytotherapy, as occurred in European/Mediterranean region.

In addition, the statistics on novel drugs developed in recent decades show that natural products are a major source of inspiration for drug development [2], with only 30% of all novel molecules (of the 1184 so-called novel chemical entities or NCEs) introduced into the market in the period 1981–2006 being pure synthetic and all others being natural products or natural product related. These statistics also show that the number of novel chemical compounds reaching the market is decreasing every year. The high costs (approx. 1000 million euros) and long duration (more than 10 years), as well as the fact that for most major ailments good medicines that are already available hampers the development of novel drugs by the pharmaceutical industry. Recently problems with serious side effects caused that several novel medicines had to be taken of the market shortly after their introduction. This does not also help to increase efforts at novel drug development.

At the same time the strong emerging economies of countries like India and China have led to greater interest in local healthcare systems, which are even considered an important (cheap) alternative to expensive treatments using Western drugs (see Chapters written by Pandey et al., Melzer and Saller, and McGregor (this volume)). Moreover, after thousands of years of extensive and widespread use of traditional medicines, the question arises as to why we should not consider these medicines again using all the tools of modern science [3, 4]. Further studies may lead to the discovery of novel modes of action, novel biologically active compounds, confirmation of traditional use, or, in the worst case, the fact that no activity is present and even that a given medicine's use can carry risks of toxicity (see Chap-

ters written by Cuzzolin and Benoni, and Benoni and Cuzzolin (this volume)). With 80% of the world's population using such traditional medicine, it makes sense to devote much more resources to such studies. The discovery of the antimalarial compound artemisinin in traditional Chinese medicine some 30 years ago has led to an efficient novel medicine used to treat malaria. But it has also led to totally new potential applications, e.g. in treating cancer (see Chapter written by Efferth (this volume)). Many more hidden gems may be found through studies of traditional medicine (Please specify the title and author you are referring to.).

One of the problems in studying traditional medicines is the totally different healthcare systems they are embedded in, e.g. different ways of classifying diseases, personalized medicines, and the complex mixtures of ingredients in traditional medicines. Current approaches to drug development may pick up some interesting compounds with high activity, but high throughput screening (HTS) will only detect compounds with strong affinity to a target enzyme or receptor; it will miss prodrugs (such as salicin the compound in *Salix* bark that in the human body is converted via glucolysis and oxidation into salicylate). Also, the synergy between compounds will not be observed in HTS, as one may, for example, envisage that artemisinin may have synergy with other antitumor compounds in a plant. The study by Stermitz et al. [5] showing the synergy between berberine and 5'-methoxyhydrnocarpin is now a classical example of synergy between two compounds from one plant. The way traditional Chinese medicines are made and the different roles that each plant traditionally was thought to play in fact point to the possible importance of synergy between ingredients [6]. A recent study on the effects of ginkgo on peripheral blood flow is a beautiful example of the totally different concept of activity of such a traditional medicine and present-day Western pharmacology. Boelsma et al. [7] showed in a placebo-controlled, double-blind clinical trial that a standardized ginkgo preparation caused different effects in different subjects, which would be unacceptable to the Western way of thinking. However, their systems-biology-type of approach showed that in fact the preparation lowered peripheral blood flow in those people who had an above-average peripheral blood flow level, increased it in those who had a below average level, and in the case of the average level did not produce any effect. In other words ginkgo normalizes peripheral blood flow, a concept that does not match the reductionist approach of drug development, using the single-target, single-compound paradigm.

On the other hand, HTS may pick up well-known compounds such as adenosine and GABA in their respective receptor binding assays, thus masking possible other active compounds, but it would confirm the rationale behind the traditional use of a traditional medicine used to treat hypertension [8].

In fact the holistic ideas of traditional healthcare systems demand a holistic approach to studying their activity [4]. First, instead of trying to find an active compound, clinical trials could be considered as a way to confirm activity before trying to understand the activity. In well-established ancient healthcare systems such as in Asia, such experiments could be done in relation to current treatments. The fact that these medicines have been used for several thousand years and are still used extensively means that acute toxicity is unlikely to occur,

though long-term toxicity might be a point for some further research (see also Chapters written by Cuzzolin and Benoni, and Benoni and Cuzzolin (this volume)).

In an approach using clinical studies, systems biology enters the picture. Systems biology aims at studying an organism under different conditions without a working hypothesis. Instead one tries to measure as many parameters as possible and use multivariate analysis or other related statistical tools to assess all the data and draw conclusions from this, i.e. the hypothesis comes afterwards. These data may include physiological parameters (e.g. blood pressure, pulse), chemical parameters (using metabolomics to measure e.g. metabolites in body fluids, metabolites in a medicinal plant), the proteome and the transcriptome. Using such a holistic approach prodrugs and synergy may be found. Also new modes of action can be revealed in this way. In any case I think that the different medical systems could learn from each other and in that way make some major steps forwards and become the source of novel ideas and concepts. Combining the best of all approaches would be to the great benefit of all people's healthcare the world over.

That said, one may also wonder why the pharmaceutical industry shows such little interest in traditional medicine. Besides the fact that the above-described problems of prodrugs and synergism do not fit their present expertise for drug development, the major reason might be that of patents. It is not impossible that the activity of a traditional medicine is due to a well-known compound, e.g. GABA or adenosine, which would thus not lead to a novel active and patentable compound. Moreover, patenting of a traditional medicine might be difficult, as a patent requires some sort of innovation, something unexpected [9]. Finding antidiabetic activity in a traditional antidiabetes medicine would thus not be accepted as an innovation, and even a compound isolated for such a plant might be difficult to patent. It would be of great value to all of humanity if any industry developing a traditional medicine with a view towards an evidence-based medicine would also be given some years of protection to be able to earn back the enormous investment needed to develop an evidence-based traditional medicine.

Ginkgo may again serve as an example. There is one ginkgo preparation (see also Chapters written by Howes and Houghton, Bhatnagar, Shah, Lehotsky et al., Melzer and Seller (this volume)) that has been studied extensively in clinical trials and shown to be active. An analysis of six different preparations for sale as an over-the-counter drug on the Dutch market, one of them being an evidence-based preparation, showed that the other five had lower, and some even very low, levels of the compounds thought to be involved in the activity, but the health claims were the same as for the proven one [10, 11]. One problem facing a country such as the Netherlands that has no clear legislation regarding phytotherapy, as the government is in general unfavourably disposed towards phytomedicines, is that a *de facto* laissez-faire policy is established that leads to the suboptimal use of herbal medicine.

1.2 Conclusion

There is an urgent need to convince Western pharmacologists that traditional medicines can be a major source of novel medicines, as well as novel concepts, but that a different approach to studying these medicines is required.

References

1. Schippmann U, Leaman D, Cunningham AB (2006) Plants as source of medicines: new perspectives. In: Bogers RJ, Craker LE, Lange D (eds) *Medicinal and Aromatic Plants – Agricultural, Commercial, Ecological, Legal, Pharmacological and Social Aspects*. Springer, Dordrecht, p 75
2. Newmann DJ, Cragg GM (2007) *J Nat Prod* 70:461
3. Verpoorte R, Kim HK, Choi YH (2005) *J Ethnopharmacol* 100:53
4. Verpoorte R, Kim HK, Choi YH (2006) Plants as source of medicines: new perspectives. In: Bogers RJ, Craker LE, Lange D (eds) *Medicinal and Aromatic Plants – Agricultural, Commercial, Ecological, Legal, Pharmacological and Social Aspects*. Springer, Dordrecht, p 261
5. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000) *Proc Natl Acad Sci USA* 97:1433
6. Wang M, Lamers RJAN, Korthout HAAJ, van Nesselrooij JHJ, Witkamp RF, van der Heijden R, Verpoorte R, van der Greef J (2005) *Phytother Res* 19:173
7. Boelsma E, Lamers RJAN, Hendriks HFJ, van Nesselrooij JHJ, Roza L (2004) *Planta Med* 70:1052
8. Schripsema J, Fung SY, Verpoorte R (1996) Screening of plant cell cultures for new industrially interesting compounds. In: DiCosmo F, Misawa M (eds) *Plant Cell Culture Secondary Metabolism. Toward Industrial Application*. CRC, Boca Raton, FL, p 1
9. Koopman J (2006) Plants as source of medicines: new perspectives. In: Bogers RJ, Craker LE, Lange D (eds) *Medicinal and Aromatic Plants – Agricultural, Commercial, Ecological, Legal, Pharmacological and Social Aspects*. Springer, Dordrecht, p 129
10. Choi YH, Choi HK, Hazekamp A, Bermejo P, Schilder YDC, Erkelens C, Verpoorte R (2003) *Chem Pharmaceut Bull* 51:158
11. Choi YH, Choi HK, Peltenburg-Looman AMG, Lefeber AWM, Verpoorte R (2004) *Phytochem Anal* 15:325